Floatz logo

Everolimus

Endocrine Breast Diseases

University of Maryland, BaltimoreSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Endocrine Breast Diseases cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Incepta Pharmaceuticals Ltd
Phase 3BB
SACUBITRIL VALSARTAN
Silesian Centre for Heart Diseases
Phase 4BB
Olaparib
AstraZeneca
Phase 2BB
Vinorelbine
Sun Yat-sen University
Phase 2BB
Capecitabine
University of Southern California
Phase 3B

View all 46 →

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →